TR201816532T4 - Spesifik olarak CD38'i tanıyan antikorlar ve bortezomib içeren antitümör kombinasyonları. - Google Patents
Spesifik olarak CD38'i tanıyan antikorlar ve bortezomib içeren antitümör kombinasyonları. Download PDFInfo
- Publication number
- TR201816532T4 TR201816532T4 TR2018/16532T TR201816532T TR201816532T4 TR 201816532 T4 TR201816532 T4 TR 201816532T4 TR 2018/16532 T TR2018/16532 T TR 2018/16532T TR 201816532 T TR201816532 T TR 201816532T TR 201816532 T4 TR201816532 T4 TR 201816532T4
- Authority
- TR
- Turkey
- Prior art keywords
- bortezomib
- specifically recognizing
- antibodies specifically
- containing antibodies
- combinations containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Farmasötik bileşim spesifik olarak CD38'i tanıyan bir antikor ve bortezomib içerir.
Description
Tarifnameye göre bilesimler tercihen parental olarak uygulanabilen bilesimlerdir. Bununla birlikte bu bilesimler lokalize bölgeler terapiler durumunda oral olarak, subkütanöz olarak veya intraperitonal olarak uygulanabilir. Parental uygulamaya yönelik bilesimler genellikle, kullanim zamaninda istege bagli olarak gerekli oldugu kadar hazirlanabilen farmasötik olarak kabul edilebilir, steril solüsyonlar veya süspansiyonlardir. Aköz olmayan solüsyonlar veya süspansiyonlarin hazirlanmasina yönelik olarak zeytinyagi, susam yagi veya sivi petrol gibi dogal bitkisel yaglar veya etil oleat gibi enjekte edilebilir organik esterler kullanilabilir. Steril aköz solüsyonlar su içinde bir ürün solüsyonundan olusabilir. Aköz solüsyonlar, pH degerinin uygun sekilde ayarlanmasi ve solüsyonun örnegin yeterli bir sodyum klorid veya glukoz miktari ile izotonik hale getirilmesi sartiyla intravenöz uygulama için uygundur. Sterilizasyon islemi, isitma yoluyla veya bilesimi olumsuz sekilde etkilemeyen herhangi bir diger sekilde gerçeklestirilebilir. Kombinasyonlar ayrica Iipozomlar formunu veya siklodekstrinler veya polietilen glikoller olarak tasiyicilar ile iliskili formu olabilir. Oral, subkütanöz veya intraperitoneal uygulamaya yönelik bilesimler tercihen aköz süspansiyonlar veya solüsyonlar olabilir. Bulusa göre kombinasyonlarda bilesenlerinin uygulanmasi bir zaman periyodunda es zamanli, ayri veya aralikli olabilir, hümanize anti-CD38 antikor miktarinin kombinasyonun agirliginca %10 ila 90 arasinda bulunmasi özellikle avantajlidir, bu bilesenin iliskili maddenin yapisi, aranan etkinlik ve tedavi edilecek kanserin yapisina göre degiskenlik göstermesi mümkündür. Bulusa göre kombinasyonlar özellikle asagidakiler dahil (ancak bunlarla sinirli olmamak üzere) birkaç kanser türünün tedavisinde faydalidir: karsinom ve adenokarsinom, mesane, meme, kolon, bas ve boyun, prostat, böbrek, karaciger, mide, serviks, tiroid ve deri karsinomlari dahil ve skuamöz hücreli karsinom dahil; Ienfoid soylu hematopoietik tümörler, multipl miyelom, lösemi, akut ve kronik Ienfositik (veya Hodgkin olmayan Ienfoma (örnegin Burkitt) dahil; miyeloid soylu hematopoietik tümörler, akut ve kronik miyelojenöz (miyeloid veya miyelositik) Iösemiler ve promiyelositik lösemi dahil; mezenkimal kökenli tümörler, fibrosarkom, osteosarkom ve rabdomiyosarkom dahil; merkezi ve periferik sinir sistemi tümörleri, astrositom, nöroblastom, gliyom ve schwannomlar dahil ve diger tümörler, melanom, teratokarsinom, kserodermi pigmentosum, keratoakantom ve seminom dahil ve CD38'in ifade edildigi henüz belirlenmedigi diger kanserler. Bunlar çogunlukla, tarifnameye ait anti-CD38 antikorlarinin benzersiz bir hareket mekanizmasina sahip olmasi nedeniyle lösemi, Ienfoma ve yaygin sekilde kullanilan antikanser ajanlarina dirençli kanserlerin tedavi edilmesine yönelik faydalidir. Bir düzenlemede kombinasyonunun antitümör etkinligi yaklasik %11-42 T/C'dir. T/C(%), tedavi edilenin Medyan tümör hacmi / kontrolün Medyan tümör hacmi X 100 olan oranidir. Diger bir düzenlemede kombinasyonunun antitümör etkinligi yaklasik %0-10 T/C'dir. Dolayisiyla, bulusun bir açisi kanserin tedavisinde kullanima yönelik yukaridaki kombinasyonlardir. Diger bir açida, tarifname ayrica kanserin tedavisine yönelik bir ilacin üretilmesine yönelik olarak yukaridaki kombinasyonlarin kullanimini kapsar. Burada açiklanan diger bir düzenleme asagidaki unsurlari içeren bir üretim maddesidir: a) bir ambalajlama materyali b) spesifik olarak CD38li taniyan bir antikor ve en az bortezomibin bir kombinasyonu, burada söz konusu antikor apoptoz, antikor bagimli hücre aracili sitotoksisite (ADCC) ve k0mpleman bagimli sitotoksisite (CDC) yoluyla bir CD38+ hücresini öldürebilir ve c) bunun söz konusu kombinasyonunun kanserin tedavi edilmesine yönelik etkili oldugu belirten, söz konusu ambalajlama materyali içinde bulunan bir etiket veya kullanma talimati. Bu örnekte tümör büyüme inhibisyonuna yönelik bulusa ait bir anti-CD38 antikor/bortezomib kombinasyonunun etkinligi in vivo gösterilmistir. Test Maddesi Uygulamasi: Hu388819 ve Bortezomib tedavileri hücre inokülasyonunundan otuz dört gün sonra baslatilmistir ve dozlar, dozlama öncesinde alinan son ölçümden belirlenen ayri hayvanlarin vücut agirliklarina bagli olarak hesaplanmistir. PBS ve hu388819 antikorunun uygulamasi intraperitoneal (IP) enjeksiyonu yoluyla ve bortezomib intravenöz (IV) enjeksiyon araciligiyla 27 kalibre, V2 inç olan bir igne ile donatilan 1.0 mL'Iik bir siringa kullanilarak kuyruk damari vasitasiyla gerçeklestirilmistir. Spesifik Çalisma Tasarimi: NCl-H929 multipl miyelom subkütanöz ksenogreft modeli fare basina 1 X 107 hücre olan subkütanöz enjeksiyon araciligiyla disi CB.17 SCID farelerde baslatilmistir, 0.1 ml serum-içermeyen kültür ortaminda süspanse edilmistir. Tümör hücre inokülasyonundan otuz-üç gün sonra, altmis-dört fare tümör hacmi (19.4 ± 1.1, Medyan ± SD) gram arasinda olmustur. Her gruptaki fareler kulaktaki bir delik ile tanimlanmistir. Tedavi gruplari PBS kontrolü (, hu3BSB19 antikoru (5.0 kombinasyon grubu (5.0 mg/kg/tedavi) ve bortezomib (1.0, 0.6 ve 0.4 mg/kg/tedavi) içermistir. PBS, hu38SB19 ve borteZOmib bir hafta boyunca haftada iki kez uygulanmistir (toplamda 2 tedavi boyunca günler 34 ve 37). Tedaviler tümör hücrelerinin inokülasyonu sonrasinda 34"üncü günde baslatilmistir. Tümör hacimleri bir kaliper kullanilarak üç boyutlu olarak haftada bir ila iki kez ölçülmüstür. Tümör hacmi asagidaki formül kullanilarak mm3 (veya mg) cinsinden ifade edilmistir: V = Uzunluk X Genislik X Yükseklik X 1/2. Vücut agirliklari test ajani toksisitesinin yaklasik bir indeksi olarak haftada iki kez ölçülmüstür. Tümör hacmi ve vücut agirligi Labcat yazilimi araciligiyla belirlenmistir ve kaydedilmistir. Sonuçlar: hu388819 antikoru ve bortezomibin tek basina ve kombinasyon halinde anti-tümör aktivitesi, subkütanöz NCI-H929 tümör ksenogreftlari, bir insan multipl miyelom modeli tasiyan disi SCID farelerde degerlendirilmistir. Asagidaki uç noktalar kullanilmistir: Toksisite, 2 %20 vücut agirligi kaybi veya 2 %10 ilaç ölümünü indükleyen dozajlarda belirtilmistir, Antitümör etkinligi asagidaki unsurun hesaplanmasi araciligiyla belirlenmistir: T/C (70) = Tedavi edilenin medyan tümör hacmi 1 Kontrolün medyan tümör hacmi X 1 00, burada bir TIC s %42 durumu, anti-tümör aktivitesinin minimum seviyesidir. T/C TR TR TR TR TR TR TR TR TR TR
Claims (1)
1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10306395 | 2010-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201816532T4 true TR201816532T4 (tr) | 2018-11-21 |
Family
ID=44168449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/16532T TR201816532T4 (tr) | 2010-12-10 | 2011-12-08 | Spesifik olarak CD38'i tanıyan antikorlar ve bortezomib içeren antitümör kombinasyonları. |
Country Status (42)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| SG188345A1 (en) | 2010-09-27 | 2013-04-30 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| PL2900232T3 (pl) | 2012-09-25 | 2018-05-30 | Morphosys Ag | Kombinacje i ich zastosowania |
| PL2968555T3 (pl) | 2013-03-13 | 2020-11-16 | Sanofi | Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib |
| JP2016528221A (ja) * | 2013-08-02 | 2016-09-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 抗クローディン１抗体およびその使用 |
| JP2016536314A (ja) * | 2013-10-31 | 2016-11-24 | サノフイ | ヒトのがんを治療するための特異的抗ｃｄ３８抗体 |
| ES2825625T3 (es) * | 2013-10-31 | 2021-05-17 | Sanofi Sa | Anticuerpos anti-CD38 específicos para tratar cánceres humanos |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| WO2016022589A2 (en) | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| UA122212C2 (uk) | 2014-09-09 | 2020-10-12 | Янссен Байотек, Інк. | Вид комбінованої терапії з застосуванням антитіла до cd38 |
| IL307913A (en) | 2014-12-04 | 2023-12-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of acute myeloid leukemia |
| MY198983A (en) | 2015-05-20 | 2023-10-06 | Janssen Biotech Inc | Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies |
| WO2016209921A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| SG11201803678SA (en) | 2015-11-03 | 2018-05-30 | Janssen Biotech Inc | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| US12161717B2 (en) | 2017-06-08 | 2024-12-10 | Black Belt Therapeutics Limited | CD38 modulating antibody agents |
| WO2018224682A1 (en) | 2017-06-08 | 2018-12-13 | Tusk Therapeutics Ltd | Cd38 modulating antibody |
| WO2019034753A1 (en) * | 2017-08-16 | 2019-02-21 | Tusk Therapeutics Ltd | ANTIBODY CD38 |
| EP3668896A1 (en) | 2017-08-16 | 2020-06-24 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| CA3088199A1 (en) | 2018-01-12 | 2019-07-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| US20210155708A1 (en) * | 2018-07-10 | 2021-05-27 | Sanofi | Combination therapies against cancer targeting cd38 and tgf-beta |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| JP7670713B2 (ja) | 2019-12-05 | 2025-04-30 | サノフィ－アベンティス・ユー・エス・エルエルシー | 皮下投与のための抗ｃｄ３８抗体の製剤 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
| US3032585A (en) | 1954-12-03 | 1962-05-01 | Nat Res Dev | Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine |
| US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| KR100663319B1 (ko) | 1997-04-14 | 2007-01-02 | 마이크로메트 에이지 | 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| DE19826517B4 (de) | 1998-06-15 | 2006-03-23 | Baxter Healthcare S.A. | Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| GB0221574D0 (en) | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| PL2511297T3 (pl) | 2004-02-06 | 2015-08-31 | Morphosys Ag | Ludzkie przeciwciała anty-CD38 i ich zastosowania |
| JP4912597B2 (ja) | 2004-07-13 | 2012-04-11 | パナソニック株式会社 | 液晶表示装置 |
| US20080057070A1 (en) | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| WO2006099875A1 (en) * | 2005-03-23 | 2006-09-28 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| AU2007302448C1 (en) | 2006-09-26 | 2019-02-14 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| TR201807983T4 (tr) | 2007-08-29 | 2018-06-21 | Sanofi Sa | İnsanlaştırılmış anti-CXCR5 antikorları, deriveleri ve kullanımları. |
| CA2712989C (en) | 2008-01-23 | 2015-10-27 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| EP2191841A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| SG188345A1 (en) * | 2010-09-27 | 2013-04-30 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| US8542056B2 (en) * | 2010-12-27 | 2013-09-24 | Stmicroelectronics S.Rl. | High voltage transmission switch, namely for ultrasound applications |
| UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| PL2968555T3 (pl) | 2013-03-13 | 2020-11-16 | Sanofi | Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib |
| JP2016536314A (ja) | 2013-10-31 | 2016-11-24 | サノフイ | ヒトのがんを治療するための特異的抗ｃｄ３８抗体 |
-
2011
- 2011-08-12 UA UAA201308680A patent/UA112170C2/uk unknown
- 2011-12-07 AR ARP110104584A patent/AR084196A1/es unknown
- 2011-12-08 CA CA2820382A patent/CA2820382C/en not_active Expired - Fee Related
- 2011-12-08 NZ NZ612055A patent/NZ612055A/en unknown
- 2011-12-08 EA EA201390850A patent/EA026406B1/ru not_active IP Right Cessation
- 2011-12-08 HR HRP20181787TT patent/HRP20181787T1/hr unknown
- 2011-12-08 PT PT11801669T patent/PT2648747T/pt unknown
- 2011-12-08 DK DK11801669.0T patent/DK2648747T3/en active
- 2011-12-08 WO PCT/EP2011/072228 patent/WO2012076663A1/en not_active Ceased
- 2011-12-08 TR TR2018/16532T patent/TR201816532T4/tr unknown
- 2011-12-08 MY MYPI2013002090A patent/MY165109A/en unknown
- 2011-12-08 EA EA201692047A patent/EA201692047A1/ru unknown
- 2011-12-08 CN CN201610701653.1A patent/CN106334187B/zh active Active
- 2011-12-08 BR BR112013014370-3A patent/BR112013014370B1/pt active IP Right Grant
- 2011-12-08 KR KR1020137017923A patent/KR101905208B1/ko active Active
- 2011-12-08 SI SI201131609T patent/SI2648747T1/sl unknown
- 2011-12-08 SG SG2013044144A patent/SG191059A1/en unknown
- 2011-12-08 JP JP2013542546A patent/JP6177133B2/ja active Active
- 2011-12-08 EP EP11801669.0A patent/EP2648747B1/en active Active
- 2011-12-08 PH PH1/2013/501183A patent/PH12013501183A1/en unknown
- 2011-12-08 ES ES11801669.0T patent/ES2694784T3/es active Active
- 2011-12-08 CN CN201180064549.1A patent/CN103282050B/zh active Active
- 2011-12-08 US US13/992,684 patent/US9314522B2/en active Active
- 2011-12-08 MA MA36092A patent/MA34816B1/fr unknown
- 2011-12-08 AU AU2011340472A patent/AU2011340472B2/en active Active
- 2011-12-08 SG SG10201600985XA patent/SG10201600985XA/en unknown
- 2011-12-08 LT LTEP11801669.0T patent/LT2648747T/lt unknown
- 2011-12-08 PL PL11801669T patent/PL2648747T3/pl unknown
- 2011-12-08 PE PE2013001392A patent/PE20140004A1/es active IP Right Grant
- 2011-12-08 HU HUE11801669A patent/HUE039893T2/hu unknown
- 2011-12-08 MX MX2017001016A patent/MX393853B/es unknown
- 2011-12-08 RS RS20181352A patent/RS57997B1/sr unknown
- 2011-12-08 EP EP18180404.8A patent/EP3412311A1/en not_active Withdrawn
- 2011-12-08 MX MX2013006566A patent/MX345257B/es active IP Right Grant
- 2011-12-09 TW TW100145632A patent/TWI596116B/zh active
- 2011-12-09 UY UY0001033791A patent/UY33791A/es not_active Application Discontinuation
-
2013
- 2013-06-05 IL IL226756A patent/IL226756B/en active IP Right Grant
- 2013-06-06 GT GT201300147A patent/GT201300147A/es unknown
- 2013-06-06 CO CO13137654A patent/CO6801634A2/es not_active Application Discontinuation
- 2013-06-06 NI NI201300050A patent/NI201300050A/es unknown
- 2013-06-07 EC ECSP13012669 patent/ECSP13012669A/es unknown
- 2013-06-07 CR CR20130270A patent/CR20130270A/es unknown
- 2013-06-07 TN TNP2013000245A patent/TN2013000245A1/fr unknown
- 2013-06-10 CL CL2013001670A patent/CL2013001670A1/es unknown
- 2013-06-10 DO DO2013000132A patent/DOP2013000132A/es unknown
- 2013-06-28 ZA ZA2013/04845A patent/ZA201304845B/en unknown
-
2018
- 2018-11-08 CY CY20181101180T patent/CY1121179T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201816532T4 (tr) | Spesifik olarak CD38'i tanıyan antikorlar ve bortezomib içeren antitümör kombinasyonları. | |
| RU2010135585A (ru) | Моноклональные антитела для лечения опухолей | |
| JP5785157B2 (ja) | Ｐｌｋ１阻害剤および抗腫瘍剤を含む治療組合せ | |
| EA026008B1 (ru) | Фармацевтическая комбинация, содержащая специфически распознающее cd38 антитело и циклофосфамид, и способ лечения злокачественной опухоли | |
| EP1272199B1 (en) | Combination therapies with vascular damaging activity | |
| JP7270235B2 (ja) | ペンタアザ大環状環複合体による組み合わせ癌免疫療法 | |
| ES2625492T3 (es) | Combinación terapéutica que comprende un inhibidor de Cdc7 y un agente antineoplásico | |
| CN110769837A (zh) | 与五氮杂大环状环配合物的联合癌症免疫疗法 | |
| US8388963B2 (en) | Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof | |
| TR201807070T4 (tr) | Kemoterapi öncesinde veya başlamasıyla birlikte parenteral balık yağı/DHA +EPA uygulaması. | |
| AU2001242581A1 (en) | Combination therapies with vascular damaging activity | |
| Koide et al. | Antitumor effect of gold as revealed by growth suppression of cultured cancer cells | |
| Mir et al. | Targeted Therapies in Combination with Metronomic Chemotherapy | |
| JPH0211513A (ja) | 制癌剤 | |
| RU2694259C2 (ru) | Способ лечения кастрационно-устойчивого рака простаты | |
| EP2049155B1 (en) | Antitumor combinations containing taxane derivatives | |
| ZA200207114B (en) | Combination therapies with vascular damaging activity. | |
| TW201315461A (zh) | 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之抗腫瘤組合 |